Enhanced Access to Affordable Medicines Act of 2022

Senate Bill 4351 - Enhanced Access to Affordable Medicines Act of 2022: Overview, Status, and Impact

Hozzl · 2022-12-29T17:33:53Z

Explore the details of Senate Bill 4351 Enhanced Access to Affordable Medicines Act of 2022 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/29/2022, 5:33 PM

Congressional Summary of S 4351

Enhanced Access to Affordable Medicines Act of 2022

This bill specifies that the Food and Drug Administration may approve generic drugs with different labels than the brand-name versions if, among other requirements, a revised label for the brand-name drug is approved within 90 days of when the generic is otherwise eligible for approval.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 4351

Bill S 4351 is currently in the status of Bill Introduced since June 6, 2022. Bill S 4351 was introduced during Congress 117 and was introduced to the Senate on June 6, 2022. Bill S 4351's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of June 6, 2022

Bipartisan Support of Bill S 4351

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 4351

Primary Policy Focus

Health

Alternate Title(s) of Bill S 4351

Enhanced Access to Affordable Medicines Act of 2022

A bill to amend the Federal Food, Drug, and Cosmetic Act to clarify the conditions under which the Secretary of Health and Human Services can approve generic drug applications with labeling temporarily different than the brand name drug, and for other purposes.